Quercetin Potentiates Doxorubicin Mediated Antitumor Effects against Liver Cancer through p53/Bcl-xl

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Wang, Guanyu ^a   Zhang, Jiawei ^b   Liu, Luying ^c   Sharma, Sherven ^d   Dong, Qinghua ^a,e  

^a ZHEJIANG UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c ZHEJIANG CANCER HOSPITAL   (China)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CASPASE INHIBITOR; DOXORUBICIN; PIFITHRIN ALPHA; PROTEIN BCL XL; PROTEIN P53; QUERCETIN; UNCLASSIFIED DRUG; Z VAD FMK;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CELL DESTRUCTION; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CANCER; LIVER INJURY; LIVER PROTECTION; LIVER TOXICITY; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TOXICITY TESTING; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; CASPASE 3; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG SYNERGISM; HUMANS; LIVER NEOPLASMS; MICE; QUERCETIN; TRANSPLANTATION, HETEROLOGOUS; TUMOR SUPPRESSOR PROTEIN P53;

MUS;

EID: 84871143693     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051764     Document Type: Article

References (51)

1. Farazi PA, Depinho RA, (2006) Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6: 674-87.
2. Nowak AK, Chow PK, Findlay M, (2004) Systemic therapy for advanced hepatocellular carcinoma: a review. Eur J Cancer 40: 1474-84.
3. Gottesman MM, Fojo T, Bates SE, (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48-58.
4. Silber JH, Barber G, (1995) Doxorubicin-induced cardiotoxicity. N Engl J Med 333: 1359-60.
5. King PD, Perry MC, (2001) Hepatotoxicity of chemotherapy. Oncologist 6: 162-76.
6. Benjamin RS, Wiernik PH, Bachur NR, (1974) Adriamycin chemotherapy. Efficacy, safety, and pharmacologic basis of an intermittent single high dose schedule. Cancer 33: 19-27.
7. Wang S, Konorev EA, Kotamraju S, Joseph J, Kalivendi S, et al. (2004) Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. intermediacy of H(2)O(2)- and p53-dependent pathways. J Biol Chem 279: 25535-43.
8. Hovorka O, Subr V, Větvička D, Kovář L, Strohalm J, et al. (2010) Spectral analysis of doxorubicin accumulation and the indirect quantification of its DNA intercalation. Eur J Pharm Biopharm 76: 514-24.
9. Mukhopadhyay P, Rajesh M, Bátkai S, Kashiwaya Y, Haskó G, et al. (2009) Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro. Am J Physiol Heart Circ Physiol 296: 1466-83.
10. Gibellini L, Pinti M, Nasi M, Montagna JP, De Biasi S, et al. (2011) Quercetin and cancer chemoprevention. Evid Based Complement Alternat Med Epub Apr 14.
11. Park MH, Min do S, (2011) Quercetin-induced downregulation of phospholipase D1 inhibits proliferation and invasion in U87 glioma cells. Biochem Biophys Res Commun. 412: 710-15.
12. Du G, Lin H, Wang M, Zhang S, Wu X, et al. (2010) Quercetin greatly improved therapeutic index of doxorubicin against 4T1 breast cancer by its opposing effects on HIF-1α in tumor and normal cells. Cancer Chemother Pharmacol 65: 277-87.
13. Du G, Lin H, Yang Y, Zhang S, Wu X, et al. (2010) Dietary quercetin combining intratumoral doxorubicin injection synergistically induces rejection of established breast cancer in mice. Int Immunopharmacol 10: 819-26.
14. Shen J, Zhang W, Wu J, Zhu Y, (2008) The synergistic reversal effect of multidrug resistance by quercetin and hyperthermia in doxorubicin-resistant human myelogenous leukemia cells. Int J Hyperthermia. 24: 151-59.
15. Staedler D, Idrizi E, Kenzaoui BH, Juillerat-Jeanneret L, (2011) Drug combinations with quercetin: doxorubicin plus quercetin in human breast cancer cells. Cancer Chemother Pharmacol 68: 1161-72.
16. Duraj J, Zazrivcova K, Bodo J, Sulikova M, Sedlak J, (2005) Flavonoid quercetin, but not apigenin or luteolin, induced apoptosis in human myeloid leukemia cells and their resistant variants. Neoplasma 52: 273-79.
17. Kaiserová H, Simůnek T, van der Vijgh WJ, Bast A, Kvasnicková E, (2007) Flavonoids as protectors against doxorubicin cardiotoxicity: role of iron chelation, antioxidant activity and inhibition of carbonyl reductase. Biochim Biophys Acta 1772: 1065-74.
18. Pei TX, Xu CQ, Li B, Zhang ZR, Gao XX, et al. (2007) Protective effect of quercetin against adriamycin-induced cardiotoxicity and its mechanism in mice. Yao Xue Xue Bao 42: 1029-33.
19. Choi KC, Chung WT, Kwon JK, Yu JY, Jang YS, et al. (2010) Inhibitory effects of quercetin on aflatoxin B1-induced hepatic damage in mice. Food Chem Toxicol 48: 2747-53.
20. Křížková J, Burdová K, Stiborová M, Křen V, Hodek P, (2009) The effects of selected flavonoids on cytochromes P450 in rat liver and small intestine. Interdiscip Toxicol 2: 201-14.
21. Tiong KH, Yiap BC, Tan EL, Ismail R, Ong CE, (2010) In vitro modulation of naturally occurring flavonoids on cytochrome P450 2A6 (CYP2A6) activity. Xenobiotica 40: 458-66.
22. Wiegand H, Boesch-Saadatmandi C, Regos I, Treutter D, Wolffram S, et al. (2009) Effects of quercetin and catechin on hepatic glutathione-S transferase (GST), NAD(P)H quinone oxidoreductase 1 (NQO1), and antioxidant enzyme activity levels in rats. Nutr Cancer 61: 717-22.
23. Kawaii S, Tomono Y, Katase E, Ogawa K, Yano M, (1999) Antiproliferative activity of flavonoids on several cancer cell lines. Biosci Biotechnol Biochem 63: 896-9.
24. Fotsis T, Pepper MS, Aktas E, Breit S, Rasku S, et al. (1997) Flavonoids, dietary-derived inhibitors of cell proliferation and in vitro angiogenesis. Cancer Res 57: 2916-21.
25. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L, (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56: 185-229.
26. Wang YA, Johnson SK, Brown BL, McCarragher LM, Al-Sakkaf K, et al. (2008) Enhanced anti-cancer effect of a phosphatidylinositol-3 kinase inhibitor and doxorubicin on human breast epithelial cell lines with different p53 and oestrogen receptor status. Int J Cancer 123: 1536-44.
27. Riad A, Bien S, Westermann D, Becher PM, Loya K, et al. (2009) Pretreatment with statin attenuates the cardiotoxicity of Doxorubicin in mice. Cancer Res 69: 695-9.
28. Nessa MU, Beale P, Chan C, Yu JQ, Huq F, (2011) Synergism from combinations of Cisplatin and oxaliplatin with quercetin and thymoquinone in human ovarian tumour models. Anticancer Res 31: 3789-97.
29. Limtrakul P, Khantamat O, Pintha K, (2005) Inhibition of P-glycoprotein function and expression by kaempferol and quercetin. J Chemother 17: 86-95.
30. Dönmez Y, Akhmetova L, İşeri ÖD, Kars MD, Gündüz U, (2011) Effect of MDR modulators verapamil and promethazine on gene expression levels of MDR1 and MRP1 in doxorubicin-resistant MCF-7 cells. Cancer Chemother Pharmacol 67: 823-8.
31. Duraj J, Zazrivcova K, Bodo J, Sulikova M, Sedlak J, (2005) Flavonoid quercetin, but not apigenin or luteolin, induced apoptosis in human myeloid leukemia cells and their resistant variants. Neoplasma 52(4): 273-9.
32. Scambia G, Ranelletti FO, Panici PB, De Vincenzo R, Bonanno G, (1994) Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target. Cancer Chemother Pharmacol 34: 459-64.
33. Yague E, Armesilla AL, Harrison G, Elliott J, Sardini A, (2003) P-glycoprotein (MDR1) expression in leukemic cells is regulated at two distinct steps, mRNA stabilization and translational initiation. J Biol Chem 278: 10344-52.
34. Li L, Lu Q, Shen Y, Hu X, (2006) Schisandrin B enhances doxorubicin-induced apoptosis of cancer cells but not normal cells. Biochem Pharmacol 71: 584-95.
35. Green DR, (2000) Apoptotic pathways: paper wraps stone blunts scissors. Cell 102: 1-4.
36. Szántó M, Rutkai I, Hegedus C, Czikora A, Rózsahegyi M, (2011) Poly(ADP-ribose) polymerase-2 depletion reduces doxorubicin-induced damage through SIRT1 induction. Cardiovasc Res 92: 430-8.
37. Llambi F, Green DR, (2011) Apoptosis and oncogenesis: give and take in the BCL-2 family. Curr Opin Genet Dev 21: 12-20.
38. Walia V, Kakar S, Elble R, (2011) Micromanagement of the mitochondrial apoptotic pathway by p53. Front Biosci 16: 749-58.
39. Vousden KH, Lu X, (2002) Live or let die: the cell's response to p53. Nat Rev Cancer 2: 594-604.
40. Moll UM, Marchenko N, Zhang XK, (2006) p53 and Nur77/TR3 - transcription factors that directly target mitochondria for cell death induction. Oncogene 25: 4725-43.
41. Chipuk JE, Green DR, (2009) PUMA cooperates with direct activator proteins to promote mitochondrial outer membrane permeabilization and apoptosis. Cell Cycle 8: 2692-6.
42. Edlich F, Banerjee S, Suzuki M, Cleland MM, Arnoult D, et al. (2011) Bcl-x(L) retrotranslocates Bax from the mitochondria into the cytosol. Cell 145: 104-16.
43. Kebieche M, Lakroun Z, Lahouel M, Bouayed J, Meraihi Z, (2009) Evaluation of epirubicin-induced acute oxidative stress toxicity in rat liver cells and mitochondria, and the prevention of toxicity through quercetin administration. Exp Toxicol Pathol 61: 161-7.
44. Alshabanah OA, Hafez MM, Al-Harbi MM, Hassan ZK, et al. (2010) Doxorubicin toxicity can be ameliorated during antioxidant L-carnitine supplementation. Oxid Med Cell Longev 3: 428-33.
45. Bulucu F, Ocal R, Karadurmus N, Sahin M, Kenar L, et al. (2009) Effects of N-acetylcysteine, deferoxamine and selenium on doxorubicin-induced hepatotoxicity. Biol Trace Elem Res 132: 184-96.
46. Kahraman A, Cakar H, Köken T, (2012) The protective effect of quercetin on long-term alcohol consumption-induced oxidative stress. Mol Biol Rep 39(3): 2789-94.
47. Odbayar TO, Kimura T, Tsushida T, Ide T, (2009) Isoenzyme-specific up-regulation of glutathione transferase and aldo-keto reductase mRNA expression by dietary quercetin in rat liver. 325(1-2): 121-30.
48. Zordoky BN, Anwar-Mohamed A, Aboutabl ME, El-Kadi AO, (2011) Acute Doxorubicin Toxicity Differentially Alters Cytochrome P450 Expression and Arachidonic Acid Metabolism in Rat Kidney and Liver. Drug Metab Dispos 39: 1440-50.
49. Dudka J, Jodynis-Liebert J, Korobowicz E, Burdan F, Korobowicz A, et al. (2005) Activity of NADPH-cytochrome P-450 reductase of the human heart, liver and lungs in the presence of (-)-epigallocatechin gallate, quercetin and resveratrol: an in vitro study. Basic Clin Pharmacol Toxicol 97: 74-9.
50. de David C, Rodrigues G, Bona S, Meurer L, González-Gallego J, et al. (2011) Role of quercetin in preventing thioacetamide-induced liver injury in rats. Toxic Pathol 39: 949-57.
51. Suematsu N, Hosoda M, Fujimori K, (2011) Protective effects of quercetin against hydrogen peroxide-induced apoptosis in human neuronal SH-SY5Y cells. Neurosci Lett 504: 223-7.